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Abstract
Objective—This analysis examined alcohol and drug use over a six-year follow-up of children in 
the Longitudinal Assessment of Manic Symptoms (LAMS) study.
Method—LAMS screened 6- to 12.9-year-old children visiting 9 child outpatient mental health 
(MH) clinics, using the Parent General Behavior Inventory 10-item mania scale. All children with 
scores ≥12 and a matched group with scores ≤12 were invited to enroll. Children were assessed 
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every 6 months. Assessments included demographics, family, MH history, child diagnoses, child 
stress, and alcohol and drug use. Univariate, bivariate, and interval censored survival analyses 
were conducted.
Results—Of those > 9 years at baseline, 34.9% used alcohol at least once with 11.9% regular 
users; 30.1% used drugs at least once with 16.2% regular users. Predictors of any alcohol use were 
parental marital status, older age at study entry, a primary diagnosis of disruptive behavior 
disorders at baseline, and number of impactful child life events. Predictors of regular alcohol use 
included parental marital status, age, and sustained high mania symptoms over the first 24 months 
of follow-up. Predictors of any drug use were single parent, parental substance use, and stressful 
child life events. Predictors of regular drug use were parental marital status, stressful child life 
events, and a baseline disruptive behavior disorder diagnosis. Baseline medications decreased the 
risk of regular drug use.
Conclusion—Longitudinal data on youth with elevated manic symptoms suggest that comorbid 
disruptive behavior disorder, manic symptom burden, family environment, and stress are 
predictors of initiation and regular use of substances.
Keywords
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INTRODUCTION
Substance use during adolescence is related to a host of serious health risks throughout the 
life span.1 Although recent data suggest that cigarette smoking and alcohol use have 
declined, many US adolescents use substances, and one group of adolescents, the 13%-20% 
of those with mental health (MH) problems, are at greatly increased risk for co-occurring 
substance use and abuse.1-3
Longitudinal data suggest that the risk for developing substance use disorders (SUD) is 
greatly elevated for adults with baseline MH disorders, particularly bipolar spectrum 
disorders (BPSD).4 Considerable data suggest that youth with BPSD are also at risk for 
SUD5 and that those youth with comorbid SUD are more likely to be less adherent to 
medications6 and have poor functional outcomes.7 However, little is known about whether 
youth with symptoms characteristic of BPSD, namely mania, are at comparable risk to 
develop SUD. Very few studies have examined the prevalence and risk factors for SUD in 
youth with manic symptoms who did not meet criteria for BPSD, although severity and 
persistence of ADHD symptoms have been shown to be related to substance use.8 
Examining children with symptoms of mania longitudinally is important because it appears 
that the BPSD begins with non-specific, non-mood pathology in children and evolves to 
mood pathology. Given that manic symptoms may be an important risk factor for SUD, the 
risk for development of SUD is likely to increase with the clinical evolution of mood 
disorder.9-11
That BPSD and mania are related to SUD is not surprising given what is known about the 
neurobiology of addiction. It is estimated that 40%-60% of the vulnerability to addiction is 
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genetic, due both to variability in drug metabolism and to the reinforcing effects of a drug, 
specifically the increase of dopamine in the limbic brain regions.12 However, development 
of SUD is multifactorial, and one pathway is a deviation in somatic and neurological 
maturation.13 When such a deviation is combined with adverse environments, such as those 
characterized by poor parenting, abuse, and stress,14 it produces affective and behavioral 
dysregulation.15 Sloboda et al.15 argue that dysregulation begins as teratogenic injury or 
difficult temperament in infancy, moves to poor impulse control/self-regulation in childhood, 
to substance use by early adolescence, and then to severe SUD by early adulthood. Tarter et 
al.16 describe youth at high risk for SUD as impulsive, exhibiting reactive aggression, 
sensation seeking, and excessive risk taking. These authors postulate that these 
characteristics emanate from disinhibition produced by dysfunction of the prefrontal cortex, 
although the precise role of temperament17 and pathology, as well as factors that modify the 
relationship, need to be further explored.18
Children with BPSD have more difficult temperaments (e.g., irritability, affective lability)19 
prior to diagnosis, considerable behavioral disinhibition, and high rates of ADHD.20 Data 
suggesting that impulsiveness and high behavioral approach system sensitivity mediate the 
relationship between BPSD and SUD21 argue strongly for examining the development of 
substance use in youth whose symptoms suggest increased risk for the development of 
BPSD. Therefore, this study aimed to: (1) determine rates of use and regular use of alcohol 
and drugs over a six-year follow-up of a cohort of children, most of whom had elevated 
symptoms of mania when enrolled; and (2) examine predictors of use/regular use of alcohol 
and drugs. Based on the findings of Wilens et al.,22 we expected that there would be 
different predictors of drug and alcohol use/regular use, so they were examined separately.
METHOD
Data for these analyses came from the Longitudinal Assessment of Manic Symptoms 
(LAMS) study. LAMS screened 6- to 12.9-year-old children at initial visit to 9 child 
outpatient clinics. Participating adults of eligible children completed the Parent General 
Behavior Inventory–10 Item Mania Scale (PGBI-10M)23,24 and 4 demographic questions. 
All children with a PGBI-10M score ≥ 12 (elevated symptoms of mania [ESM]) were invited 
to enroll in the longitudinal phase of the study, and a smaller matched group (on age, sex, 
race, insurance) of children with scores < 12 were randomly selected with replacement and 
invited.25,26 A total of 707 children (n=621 with ESM; n=86 without ESM) agreed to enroll 
in the longitudinal cohort, and 685 were eligible after the baseline assessment.
Measures
Demographics—Age, sex, race, ethnicity, health insurance status, family structure, and a 
brief medical history for the child were collected.
Family History—The Modified Family History Screen (FHS)27 collected information on 
15 psychiatric disorders, including substance abuse in biological parents.
Child Diagnoses—Children and their guardians were administered the Schedule for 
Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime 
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Episode (K-SADS-PL)28 with additional depression and manic symptom items derived from 
the Washington University in St. Louis Kiddie Schedule for Affective Disorders (Wash-U K-
SADS).29,30 The K-SADS also captures alcohol and drug dependence. Unmodified DSM-IV 
diagnostic criteria were used, and the criteria for BP-not otherwise specified (NOS) followed 
the criteria used in the Course and Outcome of Bipolar Youth Study (COBY).31 All 
diagnoses were reviewed and confirmed by a licensed child psychiatrist or psychologist.
24-Month Manic Trajectories—Using growth mixture modeling of mania symptoms 
over the first 24 months of follow-up data, Findling et al.32 found that 15% of the cohort 
belonged to 2 classes (high and rising, and unstable mania symptoms). These two classes of 
mania symptoms were characterized by high rates of diagnostic conversion to BPSD.
Child Stress—The Stressful Life Events Schedule (SLES)33 asked parents to report 
whether 80 events occurred in their child's life during the past 12 months and the impact of 
each event. Events that parents rated as having a lot or somewhat of an impact on their child 
(vs. a little or not at all) were coded as impactful. The SLES has good test-retest reliability.33
Child and Adolescent Symptom Inventory (CAASI-4)—This 163-item behavioral 
rating scale for emotional and behavioral disorders was completed by parents of children 
8-17 years of age at each visit.34 The CAASI-4 has high internal consistency (0.74-0.94) and 
significant test-retest reliability (p<.001).
Youth's Inventory (YI-4)—This 128-item self-report measure, which assesses the 
presence and severity of behavioral, cognitive, and affective symptoms described in the 
DSM-IV, was completed by participants aged 13-17 years.34,35 The YI-4 has good internal 
consistency (0.66-0.87) and test-retest reliability (r=0.54-0.92).34
Adult Self-Report Inventory (ASRI-4)—Participants aged 18 completed this 166-item 
self-report measure on the presence and severity of behavioral, cognitive, and affective 
symptoms described in DSM-IV.36
Outcomes: Substance Use/Regular Use—Three self-report measures developed by 
the Centers for Disease Control and Prevention (CDC) were used to assess whether 
participants had ever used alcohol or drugs and how often they had used alcohol and drugs 
during the past 30 days.
Students aged 10-12 years completed the middle school Youth Risk Behavior Survey 
(YRBS-MS), those aged 13-18 years completed the high school YRBS (YRBS-HS),37 and 
participants who completed high school and were 18-22 years of age completed the 
YARQ.38,39 The YRBS has good reliability (kappa ≥.60),40,41 and three measures were used 
to assess the frequency of alcohol, marijuana, and other drug use during the past 6 months 
using a 4-point ordinal scale: never, sometimes, often, very often.
Any alcohol use was defined as having more than a few sips of alcohol on at least one 
occasion (ASRI-4, CAASI-4, K-SADS, YARQ, YI-4, YRBS). Regular alcohol use was 
defined as drinking ≥3 days during the past 30 days (YRBS), drinking ≥5 drinks in a row on 
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≥2 days during the past 30 days (YRBS and YARQ), or having ≥1 drink on ≥3 days in the 
past 30 days (YARQ). Any drug use was defined as any use of marijuana, cocaine/crack/
freebase, inhalants (glue, aerosols, paints), methamphetamines, heroin, ecstasy, or 
hallucinogenics (ASRI-4, CAASI-4, K-SADS, YARQ, YI-4, YRBS). With the exception of 
the K-SADS, which assesses drug dependence, regular drug use was not measured in 
children before high school. For children high school age and beyond, regular drug use was 
defined as using drugs ≥3 times in the past 30 days (YRBS and YARQ). For each outcome, 
if the criteria were met on any of the relevant instruments, that outcome was coded as 
positive. SUD diagnoses were infrequent and, therefore, not examined.
Data Analysis
Categorical data were summarized using counts and percentages. Normally and non-
normally distributed measures were described using means ± standard deviation and median 
(25th and 75th percentiles), respectively. Bivariate associations of baseline characteristics and 
the 24-month manic trajectories32 with the outcomes were assessed via the chi-square test, 
two-sample t-test, and the Wilcoxon Rank-Sum test as appropriate. As the time interval 
during which the substance use occurred is known but the exact time it occurred is unknown, 
interval-censored survival analysis was used to examine adjusted associations with each 
outcome. Interval-censored proportional hazards models were fitted with a 2-knot spline 
baseline hazard. The results are summarized using adjusted hazard ratios (HR) and their 
95% CIs. Analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC).
Participants who reported no alcohol use at baseline (n=662, 96.6%) and no drug use at 
baseline (n=669, 97.7%) but had some data on alcohol and drug use over the 6-year follow-
up were included in the analyses of any use. The analysis of regular alcohol use included the 
579 (84.5%) participants who reported their alcohol use during the past 30 days at each 
assessment over the 6-year follow-up. Additionally, the analyses of regular drug use 
included the 429 youth who reported no drug use at baseline but provided follow-up data on 
drug use during high school or by age 18 years, as these data were not collected prior to high 
school.
RESULTS
At the 6-year follow-up, children ranged from 11.1 to 19.1 years of age, 68.2% were male, 
and 64.6% were white. When the oldest members of the cohort are 15-18 years old, 34.9% 
have used alcohol and 11.9% are regular users, while 30.1% have used drugs and 16.2% are 
regular users (Table 1).
Adjusting for age, more impactful child life events and living in a family with a parent who 
is single or remarried/living with a partner are related to regular use (Tables 1 and 2). Any 
drug use and regular drug use were also significantly related to a greater number of 
impactful child life events, being African-American, having a parent with a history of 
substance abuse, and living in a family with a parent who is single or remarried/living with a 
partner, once age was controlled (Tables 1 and 2, right-hand columns).
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Table 3 displays results of the interval-censored proportional hazards survival analysis of 
any alcohol use and regular alcohol use. Any alcohol use over the follow-up, adjusting for 
age, is predicted by parental marital status, having a primary diagnosis of disruptive 
behavior disorder (DBD) at baseline, and number of impactful child life events. Compared 
to children whose biological parents are married, children whose parent is single have a 94% 
increase in the hazard (HR=1.94), and children whose parents are remarried or living with a 
partner have a 74% increase in the hazard (HR=1.74). Children with a primary baseline 
diagnosis of DBD have a 51% increase in the hazard. Finally, each additional impactful 
child life event was associated with a 4% increase in the hazard. Predictors of regular 
alcohol use were parent marital status, baseline age, and 24-month manic trajectory. Hazards 
were significantly higher for children whose parents were single (HR=4.54) or remarried/
living with a partner (HR=4.16) compared to children whose biological parents were 
married. Children of single parents also had a significantly higher hazard (HR=2.55) 
compared to children whose parents were separated, divorced, or widowed. The hazard was 
155% higher among youth with vs. without a high and rising 24-month manic trajectory. 
Baseline diagnoses of anxiety, depression, or ADHD showed no incremental association 
with risk of alcohol use after controlling for other predictors.
Table 4 shows predictors of any and regular drug use. Any drug use in the follow-up period 
is predicted by living with a single parent, a parent history of substance abuse, and number 
of impactful child life events. A child whose parent was single had a 137% increase in the 
hazard relative to children whose biological parents were married, and an 83% increase in 
the hazard compared to children whose parents were separated, divorced, or widowed. The 
hazard was 70% higher for children whose biological parent(s) have a history of substance 
abuse. The hazard increased by 5% for each additional impactful child life event. Regular 
drug use was predicted by parent marital status, impactful child life events, a primary 
diagnosis of DBD at baseline, and the number of medications at baseline. Children whose 
biological parents were not married vs. married had significantly higher hazards. For each 
additional impactful child life event, the hazard increased by 11%. When the primary 
diagnosis at baseline was DBD, the hazard increased by 141%. Finally, every additional 
medication at baseline decreased the hazard by 33%. Again, baseline diagnoses of anxiety, 
depression, BPSD, or ADHD showed no significant association with risk of drug use after 
controlling for other predictors.
DISCUSSION
In this cohort of children enriched for ESM, children 6-8 years at baseline reported moderate 
rates over the follow-up period of any alcohol use (8.8%) and any drug use (9.1%) and lower 
rates of regular alcohol (0.8%) and drug use (2.8%). Considerably higher rates of any 
alcohol (34.9%), any drug (30.1%), regular alcohol (11.9%), and regular drug (16.2%) use 
were reported by children aged 9-12 years at baseline. Interestingly, although these children 
were selected for symptoms indicative of problems in self-regulation and impulsivity, 
hallmark predictors of substance use in the literature,42 they and their parents report rates of 
substance use lower than those from a national survey.2 There are several possible reasons 
for this finding. Substance use data in LAMS were developed from both interviews and self-
reports for the older children, while the national data were collected from self-administered 
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questionnaires. Reports of risky behaviors differ across modes of administration, and more 
anonymous self-reports may produce more accurate rates.43 Alternatively, these data may 
suggest that MH problems and seeking care for MH problems may prevent or delay the 
development of substance use, either because treatment improves child/family functioning or 
because families who seek care for their children's MH problem are more effective in 
preventing the development of risky behaviors associated with these problems. Treatment for 
MH problems has been shown to be associated with a lower risk of substance use.44 Recent 
data showed that adolescents with BPSD treated with psychostimulant medication prior to 
their first manic episode were less likely to develop SUD,45 an intriguing finding replicated 
in our data. These findings are consistent with the earlier finding of Biederman et al.,46 who 
found that adolescents with ADHD medicated at baseline, compared to those untreated, 
were less likely to develop substance use disorders. This could be due to the successful 
treatment of symptoms leading to reduced risk-taking behaviors and/or the improvement in 
symptoms leading to better academic and social functioning, thus reducing the appeal of 
regular drug use, or possibly families that could access treatment and took the trouble to do 
so had strengths that prevented substance use in other ways.
Children who lived in families with a single parent or a parent who had remarried or was 
living with a partner who was not a biological parent had elevated risks of using alcohol, 
using alcohol regularly, using drugs, and using drugs regularly. Family composition has long 
been associated with the development of substance use, usually due to less parental 
monitoring, poor parent–child interactions, or challenges in parenting due to substance use 
or MH problems.14,42
Any alcohol or drug use, and regular drug use are predicted by the number of reported 
impactful child life events, suggesting that children who experience multiple, stressful life 
events are more likely to initiate alcohol and drug use, perhaps as a means to relieve 
stress.47,48 Older age and a DBD at baseline are also associated with substance use, as has 
been previously documented.42,45,49 This suggests that children with disruptive behavior 
who experience considerable stress and who do not live with both biological parents be 
targeted for substance use prevention.
Finally, children with persistently high symptoms of mania32 were at greater risk of 
regularly using alcohol. This suggests that children with severe and persistent or recurrent 
symptoms of mania, regardless of their diagnoses, are more likely to become regular alcohol 
users. This finding is similar to that of Molina et al.,8 who found that severity and 
persistence of ADHD symptoms predicted alcohol and drug use.
As with all data, these have limitations. Participants were recruited from mental health 
clinics selected for symptoms of mania, and virtually all met criteria for one or more 
diagnoses. Thus, these results are not generalizable to all children, comparable with many 
previous studies, and may not hold in other samples of treated children, even though 
symptoms of mania are common in children visiting outpatient mental health centers. Data 
were self-reported with no other verification. It is possible that rates of alcohol and drug use 
would have been higher in this sample if data had been collected anonymously. Finally, we 
did not collect data on regular drug use during middle school.
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Use of substances in this cohort of children potentially at high risk for the development of 
substance use points to the importance of the family environment in the initiation and 
regular use of alcohol and illicit drugs. Although child psychopathology at baseline, 
specifically DBD, was a predictor of any use and regular use over a 72-month follow-up, 
stressful environments were more strongly related to such use. Childhood diagnoses of 
anxiety, depression, or ADHD were not associated with risk of later alcohol or drug use after 
controlling for family structure, life events, and manic symptoms. It appears from these data 
that stress associated with cumulating life experiences, known to have life-long health risks, 
begins early. These findings argue strongly for targeted attention to the family environments 
of dysregulated children as a means to prevent the development of future substance use.
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